Where we are, where we’ve come from, where we’re headed
Zach Haigney
By now, I am sure you've heard that TheraPsil, the Canadian non-profit advocating on behalf of palliative patients for compassionate use of psilocybin …
Zach Haigney
Policy Updates Compassionate Use Milestone Yesterday the psychedelic world awaited with bated breath the announcement from Canadian Health Minister Pat…
Zach Haigney
Announcing a New Project: The Trip Report Community In the last few months, we’ve seen a wave of psychedelic companies form and some have even gone pub…
Zach Haigney
Earlier today I published a post citing two stories about Christian Angermayer's involvement in a transaction unrelated to the psychedelic ecosystem. T…
Zach Haigney
Follow up: Synthesis/Manufacturing Conundrum At every level of education, teachers encourage students to ask questions when they don't understand somet…
Zach Haigney
MindMed Update MindMed Concludes Phase 1 dosing of 18-MC: “Mind Medicine… has concluded dosing in a Phase 1 Single Ascending Dose (SAD) study of 18-MC.…
Zach Haigney
“Even though there are snakes in the world, it’s good to go barefoot so you can feel the grass between your toes.” —Ted Roberts The War on Drugs, the n…
Zach Haigney
DMT Served Three Ways On Wednesday, ATAI announced it's latest portfolio company, Viridia Life Sciences, which is developing DMT for "a variety of ment…
Zach Haigney
ATAI Enters the DMT Race I was about to hit send when I got this announcement, here are highlights from the FierceBiotech announcement: “The company ai…
Zach Haigney
Hello, and welcome to The Trip Report Pro for Monday, July 20th. I hope you had a great weekend. The summer months (in the North) seem to be cooling th…
Zach Haigney
Software-Assisted Psychedelic-Assisted Psychotherapy: Part 3/n
Zach Haigney